• Platform & Pipeline
    • Opportunity
    • CAR T-Cell Therapy
    • Pipeline
    • Clinical Trials and Expanded Access
  • Patients
    • Experience
    • Stiff Person Syndrome
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Lupus Nephritis
    • Systemic Sclerosis
  • Inside Kyverna
    • Leadership
    • Mission & Values
  • Knowledge Center
    • Publications
    • Videos
  • Investors
  • News
  • Careers
  • Contact
← Back

Browse Jobs

Clinical

Associate Director, TMF Lead

Remote
View

Medical Director/Sr. Medical Director, Clinical Development

Remote
View

Sr. Clinical Trial Manager

Remote
View

Commercial

Director, CAR T Channel Strategy & Operations

Remote
View

Sr. Director, Field Market Access

Remote
View

Sr. Director, Marketing Promotions

Emeryville, CA
View

Vice President, Sales

Remote
View

G&A

Accounts Payable Specialist (Coupa) Contract

Remote
View

Sr. Director, Corporate Compliance

Remote
View

Manufacturing

Associate Director, External Manufacturing and Supply

Emeryville, CA
View

Medical Affairs

Director of Training, Global Medical Affairs

Remote
View

Medical Science Liaison (MSL)/Senior Medical Science Liaison (MSL) - West Coast

Remote
View

Project Management

Executive Director, Lifecycle Lead

Remote
View

Vice President, Lifecycle Leader

Remote
View

Regulatory Affairs

Executive Director, Medical Writing

Remote
View

Executive Director, Regulatory Affairs

Remote
View

Medical Writer, Regulatory (Contract)

Remote
View

Sr Manager, Medical Writing

Remote
View

Links

  • Home
  • Platform & Pipeline
  • Patients
  • Inside Kyverna
  • Knowledge Center
  • Investors
  • Careers
  • Contact

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

  • Privacy Policy (US)
  • Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress